uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial
Oslo Univ Hosp, Div Pediat & Adolescent Med, Oslo, Norway;Univ Oslo, Inst Clin Med, Oslo, Norway.
Oslo Univ Hosp, Div Pediat & Adolescent Med, Oslo, Norway;Univ Oslo, Inst Clin Med, Oslo, Norway.
Oslo Univ Hosp, Div Pediat & Adolescent Med, Oslo, Norway;Univ Oslo, Inst Clin Med, Oslo, Norway.
Oslo Univ Hosp, Div Pediat & Adolescent Med, Oslo, Norway.
Show others and affiliations
2019 (English)In: Pediatric Allergy and Immunology, ISSN 0905-6157, E-ISSN 1399-3038, Vol. 30, no 6, p. 638-645Article in journal (Refereed) Published
Abstract [en]

Background Improved quality of life (QoL) after oral immunotherapy (OIT) in peanut allergic children is often reported by their parents, while the child's perspective is less clear. Objective We aimed to explore whether 2 years of OIT improved QoL in children with peanut allergy and to identify factors influencing change in QoL. Methods In the open-labeled TAKE-AWAY peanut OIT trial including children with anaphylaxis to peanuts, 57 were randomized to OIT and 20 to observation. The Pediatric Quality of Life Inventory Version 4.0 was completed by parents and children at enrollment (Y-0), after 1 year (end of updosing; Y-1) and after 2 years (Y-2) of OIT. Minimally clinically important difference (MCID) is >= 5.3. Perceived treatment burden was recorded by visual analogue scales, including adverse events (AEs). An open food challenge (OFC) was performed at Y-2. Results At Y-2, 18 children had discontinued OIT and 2 of 39 OIT children refused OFC, while 35 of 37 were desensitized to 7500 mg peanut protein. From Y-0 to Y-2,Y- the mean change (95% confidence intervals) in QoL was 4.4 (0.5, 8.3) among child self-reports and twice as large among parental proxy reports (9.3 [4.3, 14.3]; both P < 0.0001), without significant improvement among the controls. The change in QoL was significantly different from the controls for the parental proxy reports only (P = 0.002). Neither treatment burden nor AEs significantly predicted changes in QoL. Conclusion Two years of OIT improved child-QoL as reported by parents, but not by the children, suggesting that parents may overestimate improvement in child-QoL by OIT.

Place, publisher, year, edition, pages
WILEY , 2019. Vol. 30, no 6, p. 638-645
Keywords [en]
child, desensitization, double-blind placebo-controlled food challenge, oral immunotherapy, peanut allergy, perceived treatment burden, quality of life, self- and proxy reports, visual analogue scale
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:uu:diva-396131DOI: 10.1111/pai.13066ISI: 000479459400001PubMedID: 31013372OAI: oai:DiVA.org:uu-396131DiVA, id: diva2:1368837
Available from: 2019-11-08 Created: 2019-11-08 Last updated: 2019-11-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Borres, Magnus P

Search in DiVA

By author/editor
Borres, Magnus P
By organisation
Department of Women's and Children's Health
In the same journal
Pediatric Allergy and Immunology
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf